Linaclotide

Type: Keyphrase
Name: Linaclotide
First reported Aug 28 2014 - Updated Aug 28 2014 - 1 reports

Advances in Management of Constipation-predominant IBS

Abdulmajeed, A., Rabab, M., Sliem, H. and Hebatallah, N. (2011) Pattern of irritable bowel syndrome and its impact on quality of life in primary health care center attendees, Suez governorate, Egypt. Pan Afr Med J 9: 5.Andresen, V., Camilleri, M., Busciglio, ... [Published General Medicine eJournal - Aug 28 2014]
First reported Aug 18 2014 - Updated Aug 18 2014 - 1 reports

July 2014 Boxed Warning For Linzess: Irritable Bowel Syndrome / Constipation Drug May Be Unsafe And Dangerous For Children

FDA Drug Alert Warns That Linzess Should Not Be Used In Children Under Age 6 And Neither Safety Nor Efficacy Established For Those Under 18 Years Old (Posted by Tom Lamb at DrugInjuryWatch.com ) Linzess (linaclotide) Was approved by the FDA ... [Published Drug Injury Watch - Aug 18 2014]
First reported Aug 16 2014 - Updated Aug 16 2014 - 1 reports

Treating IBS

An estimated 5-15% of the world's population has Irritable Bowel Syndrome (IBS), a condition that can cause symptoms such as abdominal pain, diarrhoea or constipation, cramping and bloating, and gas. It can affect people at any age but is especially common ... [Published Bangladesh Daily Star - Aug 16 2014]
First reported Aug 12 2014 - Updated Aug 12 2014 - 1 reports

Stable solid formulation of a GC-C receptor agonist polypeptide suitable for oral administration

Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Cys Glu Tyr ... [Published Free Patents Online - Aug 12 2014]
First reported Aug 11 2014 - Updated Aug 11 2014 - 1 reports

New Treatment Guidelines for Irritable Bowel Syndrome

News Categories ACG Task Force offers scientifically based recommendationsNew guidelines have been issued with regard to the management of irritable bowel syndrome (IBS) and chronic idiopathic constipation. The updated guidelines were published as a supplement ... [Published PT Community - Aug 11 2014]
First reported Aug 08 2014 - Updated Aug 08 2014 - 2 reports

Experts Issue Guidelines for Treating Irritable Bowel Syndrome

By Randy DotingaFRIDAY, Aug. 8, 2014 (HealthDay News) -- Newly released guidelines for the treatment of irritable bowel syndrome and a type of constipation known as chronic idiopathic constipation reveal a number of proven treatments for these two common ... [Published Bio-Medicine - Aug 08 2014]
First reported Aug 05 2014 - Updated Aug 06 2014 - 2 reports

ACG updates recommendations for management of IBS, chronic idiopathic constipation

The American College of Gastroenterology has published an updated systematic review of data for the management of irritable bowel syndrome and chronic idiopathic constipation.Updating data last compiled in 2009, the review was designed to provide physicians ... [Published Orthopedics Today - Aug 05 2014]
First reported Aug 05 2014 - Updated Aug 05 2014 - 1 reports

Ironwood Pharmaceuticals' (IRWD) CEO Peter Hecht on Q2 2014 Results - Earnings Call Transcript

OperatorGood day, ladies and gentlemen. And welcome to the Ironwood Pharmaceuticals Second Quarter 2014 Investor Update Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and ... [Published Seeking Alpha - Aug 05 2014]
First reported Aug 04 2014 - Updated Aug 04 2014 - 1 reports

Ironwood Pharmaceuticals Provides Second Quarter 2014 Investor Update

– 36% growth in total LINZESS® (linaclotide) prescriptions quarter over quarter – – Second quarter LINZESS U.S. net product sales of $62.7 million – CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc.... ... [Published Wall Street Business Network - Aug 04 2014]
First reported Aug 04 2014 - Updated Aug 04 2014 - 1 reports

Researchers want to know how newest IBS drug helps stomach pain

Dr. Satish S.C. Rao is Chief of the Section of Gastroenterology and Hepatology at the Medical College of Georgia at Georgia Regents University and founding Director of the GRU Digestive Health Center. Credit: Phil JonesThe newest drug for irritable bowel ... [Published Medical Xpress - Aug 04 2014]
First reported Aug 01 2014 - Updated Aug 01 2014 - 1 reports

Dr. Satish Rao Heads IBS Drug Linzess Study at Medical College of GA

Augusta, GA -Irritable Bowel Syndrome is a condition that affects one in 15 people, primarily women between the ages of 30-50.The symptoms aren't nice: painful diarrhea, constipation or bouts of both.Research is taking place now, at the Medical College ... [Published WJBF-TV - Aug 01 2014]
Entities: IBS, Satish Rao, Drugs
First reported May 01 2014 - Updated May 01 2014 - 3 reports

Ironwood and Forest to Present Linaclotide Data at Digestive Disease Week® 2014

CAMBRIDGE, Mass. & NEW YORK--(EON: Enhanced Online News)--Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) and Forest Laboratories, Inc. (NYSE:FRX) announced today they will present linaclotide-related data during Digestive Disease Week® 2014 in Chicago, ... [Published EON Science - May 01 2014]

Quotes

...The biggest change is the development of medicines that work directly in the digestive tract. "They do not have to be absorbed into the bloodstream to be effective in the [gastrointestinal tract" Quigley says
"We now have a better opportunity to improve the lives of our patients" Quigley said
...guidance to make clinical decisions about these conditions based on a thorough assessment of the evidence," a coauthor said in a statement. "However, it is important that patients talk with their doctors about their treatment options, as there is no one-size-fits-all approach to managing IBS or chronic constipation."
It's been several years since the last treatment guideline updates for either of these conditions. "It was felt that there had been significant developments in both areas,” says Eamonn M M Quigley, MD, who co-wrote the guidelines. He is chief of gastroenterology and hepatology at Houston Methodist Hospital and Weill Cornell Medical College in Houston, Texas."

More Content

All (39) | News (19) | Reports (0) | Blogs (20) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Advances in Management of Constipation-predomin... [Published General Medicine eJournal - Aug 28 2014]
The Newest IBS Medicines [Published ThirdAge - Aug 21 2014]
July 2014 Boxed Warning For Linzess: Irritable ... [Published Drug Injury Watch - Aug 18 2014]
Treating IBS [Published Bangladesh Daily Star - Aug 16 2014]
IBS, Chronic Constipation: New Guidelines Issued [Published eMedicine Health - Aug 14 2014]
Stable solid formulation of a GC-C receptor ago... [Published Free Patents Online - Aug 12 2014]
New Treatment Guidelines for Irritable Bowel Sy... [Published PT Community - Aug 11 2014]
Experts Issue Guidelines for Treating Irritable... [Published Bio-Medicine - Aug 08 2014]
ACG: New guidelines issued for irritable bowel ... [Published Medical Xpress - Aug 08 2014]
IBS, Chronic Constipation: New Guidelines Issued [Published WPXI - Aug 08 2014]
IBS, Chronic Idiopathic Constipation: New Guide... [Published Diabetes Care - Aug 06 2014]
ACG updates recommendations for management of I... [Published Orthopedics Today - Aug 05 2014]
American College of Gastroenterology Releases E... [Published Newswise - Aug 05 2014]
Ironwood Pharmaceuticals' (IRWD) CEO Peter Hech... [Published Seeking Alpha - Aug 05 2014]
Ironwood Pharmaceuticals Provides Second Quarte... [Published Wall Street Business Network - Aug 04 2014]
Researchers want to know how newest IBS drug he... [Published Medical Xpress - Aug 04 2014]
Dr. Satish Rao Heads IBS Drug Linzess Study at ... [Published WJBF-TV - Aug 01 2014]
Venrock Closes its 7th fund: $450M to Put Where... [Published Bostinno - Jul 31 2014]
Elobixibat and Its Role in Chronic Idiopathic C... [Published General Medicine eJournal - Jul 28 2014]
LINZESS (Linaclotide) Capsule, Gelatin Coated [... [Published DailyMed Drug Label Updates for the last seven ... - Jul 24 2014]
Ironwood and Forest to Present Linaclotide Data... [Published EON Science - May 01 2014]
Ironwood and Forest to Present Linaclotide Data... [Published Business Wire Science: Science News - May 01 2014]
Ironwood and Forest to Present Linaclotide Data... [Published Business Wire Health News - May 01 2014]
The Right Treatment for Irritable Bowel Syndrome [Published ThirdAge - Apr 25 2014]
Ironwood and Forest Launch New Direct-to-Consum... [Published Business Wire Photo/Multimedia News - Apr 10 2014]
Ironwood and Forest Launch New Direct-to-Consum... [Published Business Wire Health News - Apr 10 2014]
Ironwood and Forest Launch New Direct-to-Consum... [Published Business Wire News with Multimedia - Apr 10 2014]
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Mar 25 2014]
Ironwood Receives Notice of Allowance for Metho... [Published EON Environment - Feb 10 2014]
Ironwood Receives Notice of Allowance for Metho... [Published EON Transportation - Feb 10 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
July 2014 Boxed Warning For Linzess: Irritable ... [Published Drug Injury Watch - Aug 18 2014]
FDA Drug Alert Warns That Linzess Should Not Be Used In Children Under Age 6 And Neither Safety Nor Efficacy Established For Those Under 18 Years Old (Posted by Tom Lamb at DrugInjuryWatch.com ) Linzess (linaclotide) Was approved by the FDA ...
LINZESS (Linaclotide) Capsule, Gelatin Coated [... [Published DailyMed Drug Label Updates for the last seven ... - Jul 24 2014]
Updated Date: Jul 17, 2014 EST ...
Ironwood and Forest to Present Linaclotide Data... [Published EON Science - May 01 2014]
CAMBRIDGE, Mass. & NEW YORK--(EON: Enhanced Online News)--Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) and Forest Laboratories, Inc. (NYSE:FRX) announced today they will present linaclotide-related data during Digestive Disease Week® 2014 in Chicago, ...
Ironwood and Forest to Present Linaclotide Data... [Published Business Wire Science: Science News - May 01 2014]
CAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) and Forest Laboratories, Inc. (NYSE:FRX) announced today they will present linaclotide-related data during Digestive Disease Week® 2014 in Chicago, May 3 through ...
Ironwood and Forest to Present Linaclotide Data... [Published Business Wire Health News - May 01 2014]
CAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) and Forest Laboratories, Inc. (NYSE:FRX) announced today they will present linaclotide-related data during Digestive Disease Week® 2014 in Chicago, May 3 through ...
1 2 3 4
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.